adjuvanted pneumococcal conjugate vaccine

Adjuvanted pneumococcal conjugate vaccine is a vaccine candidate developed by LiteVax B.V. for the prevention of pneumococcal infections caused by *Streptococcus pneumoniae*. The vaccine utilizes LiteVax's proprietary LVX adjuvant, which is a synthetic carbohydrate-based molecule (specifically a sucrose fatty acid sulfate ester). This adjuvant is designed to enhance the immunogenicity of the pneumococcal polysaccharides that are conjugated to carrier proteins, potentially allowing for a more robust immune response, improved protection in vulnerable populations, or dose-sparing. The vaccine typically targets multiple serotypes (e.g., PCV10) of *S. pneumoniae* to provide broad coverage against pneumonia, meningitis, and sepsis.

Other names

LVX-adjuvanted pneumococcal conjugate vaccine